Immunic Inc. CEO Daniel Vitt Highlights Advances in MS Treatment on World MS Day [Video]

Immunic Inc (NASDAQ:IMUX) CEO Daniel Vitt joined Steve Darling from Proactive to discuss the ongoing challenges and recent developments in treating multiple sclerosis (MS). This interview took place in conjunction with World MS Day, a day dedicated to raising global awareness about this debilitating disease. Vitt emphasized the significant unmet medical need for effective treatments, noting that MS affects approximately 2.8 million people worldwide. The disease often leads to progressive physical disability, with many patients eventually requiring wheelchairs for mobility. Vitt explained that early diagnosis is crucial for MS, as it allows for more timely and effective intervention, which can significantly slow the progression of the disease. He highlighted Immunic’s innovative approach to MS treatment, which targets both inflammation and neuroprotection.

This strategy is designed to address the complex nature of MS, which involves both inflammatory and neurodegenerative processes. Immunic’s lead drug candidate, vidofludimus calcium, is currently in clinical development for both relapsing …